Inhaled nintedanib for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with IPF according to current guidelines.
- You either haven't taken any IPF treatment before, or you've been on a steady dose of pirfenidone or nerandomilast for at least 3 months.
- You weigh more than 88 pounds (40 kg).
- If you can become pregnant, you agree to use approved birth control and have negative pregnancy tests. If you can father a child, you agree to use approved birth control and not donate sperm during the study and for a few months after.
- You are willing to follow the study rules, attend visits, and complete lung function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests whether adding dextromethorphan (a common cough medicine) to nintedanib (a lung-fibrosis drug) helps slow lung damage in people with idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes scarred and stiff. The study lasts 12 weeks plus one follow-up visit.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.